Literature DB >> 19702557

The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers.

Michel Bourin1, Franck Chenu, Martine Hascoët.   

Abstract

Antidepressant drugs modify in different ways the activity of neurons, by increasing monoamines levels and by modulating ion channels. Sodium channels are molecular targets for antiepileptic drugs, which can also be mood stabilizers (i.e. lamotrigine, topiramate, phenytoin, carbamazepine, valproic acid). After a short overview on the sodium channels and the interaction with antidepressants and mood stabilizers, a comparison of the activity of both antidepressants and mood stabilizers with the addition of veratrine (sodium channel opener) on the forced swimming test (FST) in mice was presented. By comparing the antidepressant-like effect of the antidepressants (paroxetine, imipramine and desipramine) with the one of anticonvulsants (lamotrigine, phenytoin and topiramate) on the FST, it seems that the mechanism of action of anticonvulsants and antidepressants are different, because veratrine limits the activity of anticonvulsants but not of antidepressants. The anticonvulsants topiramate and phenytoin reduce the immobility time in the FST in a range of time similar to those induced by antidepressants, suggesting that the FST could be sensitive to both drugs. The magnitude of antidepressant-like effect of the lamotrigine (acting through an increase in monoaminergic neurotransmission and a blockade of sodium channels) in the FST is greater than what is obtained after administration of the other drugs, suggesting that this dual activity could be used as an augmentation strategy. Authors conclude that the development of new drugs acting on sodium channels could potentially be of interest as antidepressants, but also as augmentation strategies for classical antidepressants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702557     DOI: 10.2174/138945009789735138

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

1.  The antidepressant-like effects of topiramate alone or combined with 17β-estradiol in ovariectomized Wistar rats submitted to the forced swimming test.

Authors:  Miguel Molina-Hernández; N Patricia Téllez-Alcántara; Jorge I Olivera-López; M Teresa Jaramillo
Journal:  Psychopharmacology (Berl)       Date:  2013-08-24       Impact factor: 4.530

2.  Tricyclic Antidepressants Modulate Stressed Mitochondria in Glioblastoma Multiforme Cells.

Authors:  Anna M Bielecka-Wajdman; Tomasz Ludyga; Grzegorz Machnik; Miłosz Gołyszny; Ewa Obuchowicz
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

Review 3.  Industrial Applications of Dinoflagellate Phycotoxins Based on Their Modes of Action: A Review.

Authors:  Kichul Cho; Jina Heo; Jinwook Han; Hyun Dae Hong; Hancheol Jeon; Hyun-Ju Hwang; Chang-Yu Hong; Daekyung Kim; Jong Won Han; Kyunghwa Baek
Journal:  Toxins (Basel)       Date:  2020-12-18       Impact factor: 4.546

4.  Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.

Authors:  Fabrizio Stocchi; Angelo Antonini; Daniela Berg; Bruno Bergmans; Wolfgang Jost; Regina Katzenschlager; Jaime Kulisevsky; Per Odin; Francesc Valldeoriola; K Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2022-02-21

5.  Efficacy and safety of daily home-based transcranial direct current stimulation as adjunct treatment for bipolar depressive episodes: Double-blind sham-controlled randomized clinical trial.

Authors:  Jangwon Lee; Chan Woo Lee; Yoonjeong Jang; Ji Seon You; Yun Seong Park; Eunjeong Ji; Hyeona Yu; Sunghee Oh; Hyun A Ryoo; Nayoung Cho; Ji Yoon Park; Joohyun Yoon; Ji Hyun Baek; Hye Youn Park; Tae Hyon Ha; Woojae Myung
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

Review 6.  Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer.

Authors:  Kedar S Prabhavalkar; Nimmy B Poovanpallil; Lokesh K Bhatt
Journal:  Front Pharmacol       Date:  2015-10-23       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.